Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.33 |
| ▸ | RELA | Q04206 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PYGB | P11216 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7403136 | 1.00 | GAA (0.37) | GAANFKB1NFKB2RELAKMT2A | |
| SCHEMBL7801965 | 1.00 | GAA (0.37) | GAANFKB1NFKB2RELAKMT2A | |
| SCHEMBL1661965 | 0.84 | GAA (0.55) | GAANFKB1NFKB2RELA | |
| SCHEMBL8355012 | 0.84 | GAA (0.55) | GAANFKB1NFKB2RELA | |
| SCHEMBL1661966 | 0.84 | GAA (0.55) | GAANFKB1NFKB2RELA | |
| SCHEMBL4655182 | 0.81 | KDM4E (0.36) | — | |
| SCHEMBL10873133 | 0.81 | KDM4E (0.36) | — | |
| SCHEMBL8634789 | 0.79 | CTRB1 (0.35) | — | |
| SCHEMBL3596240 | 0.79 | CTRB1 (0.35) | — | |
| SCHEMBL553861 | 0.79 | CTRB1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110217234-A1 | IMAGING LIGANDS | GENERAL ELECTRIC COMPANY | 2011-09-08 | — | — | US | disclosed |
| US-20010008947-A1 | 2-AMINO-4-PHENYL-4-OXO-BUTYRIC ACID DERIVATIVES | VARASI MARIO (IT) | 2001-07-19 | — | — | US | disclosed |
| US-6084130-A | FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0923542-A1 | ARYL SUBSTITUTED CYCLIC AMINES AS SELECTIVE DOPAMINE D3 LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
| EP-0662948-B1 | 2-AMINO-4-PHENYL-4-OXO-BUTYRIC ACID DERIVATIVES WITH KYNURENINASE AND/OR KYNURENINE-3-HYDROXYLASE INHIBITING ACTIVITY | PHARMACIA & UPJOHN SPA (IT) | 1998-10-07 | — | — | EP | disclosed |
| WO-1997045403-A1 | ARYL SUBSTITUTED CYCLIC AMINES AS SELECTIVE DOPAMINE D3 LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-04 | — | — | WO | disclosed |
| EP-0662948-A1 | 2-AMINO-4-PHENYL-4-OXO-BUTYRIC ACID DERIVATIVES WITH KYNURENINASE AND/OR KYNURENINE-3-HYDROXYLASE INHIBITING ACTIVITY | PHARMACIA & UPJOHN S.p.A. (IT) | 1995-07-19 | — | — | EP | disclosed |
| WO-1995003271-A1 | 2-AMINO-4-PHENYL-4-OXO-BUTYRIC ACID DERIVATIVES WITH KYNURENINASE AND/OR KYNURENINE-3-HYDROXYLASE INHIBITING ACTIVITY | PHARMACIA S.P.A. (IT) | 1995-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110217234-A1 | IMAGING LIGANDS | DRD2, SLC6A3, DRD3 | GAA 1985/4885NFKB1 4040/4885NFKB2 4333/4885 |
| US-20010008947-A1 | 2-AMINO-4-PHENYL-4-OXO-BUTYRIC ACID DERIVATIVES | KYNU, KMO, ABAT | GAA 363/4885NFKB1 677/4885NFKB2 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.